All of the following statements about nateglinide are true except?
**Core Concept**
Nateglinide is a **D-phenylalanine** derivative that stimulates **insulin secretion** from the pancreas. It is used in the management of **type 2 diabetes mellitus**. Nateglinide acts by closing **potassium channels** in the pancreatic beta cells.
**Why the Correct Answer is Right**
Since the correct answer is not provided, let's discuss the general mechanism of nateglinide. Nateglinide binds to a specific site on the **sulfonylurea receptor**, which is part of the **ATP-sensitive potassium channel**. This binding causes the channel to close, leading to **depolarization** of the beta cell, opening of **voltage-dependent calcium channels**, and ultimately, **insulin release**.
**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific statement, it's challenging to provide a detailed explanation. However, if the statement claimed nateglinide was a long-acting insulin secretagogue, it would be incorrect because nateglinide has a **short duration of action**.
**Option B:** Similarly, without the statement, we can't provide a specific reason. But if it stated nateglinide was used for **type 1 diabetes**, that would be incorrect as it's primarily used for **type 2 diabetes**.
**Option C:** If the statement said nateglinide worked by increasing **glucagon** levels, that would be incorrect because nateglinide primarily works by stimulating **insulin secretion**.
**Option D:** If the statement claimed nateglinide had no effect on **postprandial glucose** levels, that would be incorrect because nateglinide is known to decrease **postprandial glucose** peaks.
**Clinical Pearl / High-Yield Fact**
Nateglinide is particularly useful for controlling **postprandial blood glucose** levels due to its rapid onset and short duration of action. It's often used in combination with other **antidiabetic drugs** to achieve better **glycemic control**.
**Correct Answer:**